

---

ongoing trials - trial from [www.clinicaltrials.gov](http://www.clinicaltrials.gov)

## **Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations - Phase 2 - Not yet recruiting**

**Code:** NCT05641298

**Year:** 2022

**Date:** December 2022

**Author:** Aceragen

### **Study design (if review, criteria of inclusion for studies)**

Interventional - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment

### **Participants**

Cystic Fibrosis|Cystic Fibrosis Pulmonary Exacerbation - 12 Years and older (Child, Adult, Older Adult)

### **Interventions**

Drug: Sodium Fusidate|Drug: Placebo

### **Outcome measures**

Desirability in outcome ranking (DOOR)

<https://ClinicalTrials.gov/show/NCT05641298>

### **Keywords**

Sodium Fusidate; other anti-bacterial agents; Anti-Bacterial Agents; pharmacological\_intervention;